These exploratory analyses of the phase 3 SIMPLIFY-2 trial focused on JAK inhibitor-experienced patient subgroups for whom anemia management is typically a key consideration: patients with Hb of < 100 g/L and patients who were non-TI. Here, GSTM1 is linked to anemia (phenotype).